CMS Confirms Coverage of Kerecis Fish-Skin Products by Medicare
November 14, 2024
Menu
Kerecis is a biotechnology company that develops, manufactures and markets regenerative grafts from Omega3-rich fish skin. The company’s initial product (Kerecis Omega3 Wound) has been approved by the FDA and is being marketed in the U.S. and several international markets. Kerecis has in the last two years transitioned from being a research and development company into commercialization and is experiencing rapid growth and outstanding patient results.
Kerecis has offices in the United States (Arlington, Virginia and Minneapolis, Minnesota), Iceland (Reykjavik and Isafjordur) and Hamburg (Germany).
View open positions below or contact us through careers@kerecis.com
Kerecis is an equal opportunity employer. Qualified applicants will receive consideration for employment without regard to race, ethnicity, color, religion, sex, gender identity, sexual orientation, national origin, disability, or protected veteran status.
© 2010-2024 Kerecis. All Rights Reserved